APA Alıntı

Géczi, L., Bodoky, G., Rokszin, G., Fábián, I., & Torday, L. (2020). Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma. Pathol Oncol Res.

Chicago Stili Alıntı

Géczi, Lajos, György Bodoky, György Rokszin, Ibolya Fábián, ve László Torday. "Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma." Pathol Oncol Res 2020.

MLA Alıntı

Géczi, Lajos, et al. "Survival Benefits of Second-line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma." Pathol Oncol Res 2020.